Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of JNJ-54781532 Formulations
NCT02117505Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of peficitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 48 hours, Time to Reach Maximum Concentration at 48 hours and 2 more. Started Apr 2014; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02117505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117505.